The Effects of Levosimendan During Mitral Valve Surgery
Mitral Valve Stenosis With Incompetence or Regurgitation
About this trial
This is an interventional prevention trial for Mitral Valve Stenosis With Incompetence or Regurgitation focused on measuring levosimendan, mitral valve surgery, cardiopulmonary bypass, serum creatinine, estimated glomerular filtration rate, ejection fraction
Eligibility Criteria
Inclusion Criteria:
- diagnosis of mitral valve insufficiency with or without coronary artery disease and a LVEF of ≤ 45 %.
Exclusion criteria:
- unstable angina,
- diabetes mellitus treated with insulin, clinical findings of acute or chronic renal failure (sCr > 1.5 mg dL-1),
- severe hepatic disease (alanine aminotransferase or aspartate aminotransferase > 100 U litre L-1),
- severe chronic obstructive pulmonary disease (forced expired volume in 1 s < 50 % of predicted or < 2.0 litre),
- a history of prior CABG surgery or myocardial infarction (MI) within the previous month,
- emergent operations,
- patients on inotropic support before operation,
- aortic valvular disease, and
- infective endocarditis.
Sites / Locations
- Kartal Kosuyolu High Speciality Training and Research Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Levosimendan, inotropic agent
Control
In the levosimendan group, levosimendan will be used in addition to standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)for 24 hours.Levosimendan dosage; a loading dose of levosimendan (6 μg kg-1) will be administered after removal of the aortic cross-clamp, followed by an infusion of levosimendan at a dose of 0.1 μg kg-1 min-1.
In the control group, only standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)will be administered